06 August 2018
Visiongain has launched a new pharma report Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028: ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretic, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Chronic kidney disease (CKD) is a major risk multiplier factor for cardiovascular disease, diabetes, hypertension, inflammatory disease of kidney (glomerulonephritis), and aging. CKD may lead to kidney injury and sometimes to complete loss of kidney function, thus leading to renal replacement therapy. According to World Kidney Day, a global awareness campaign, an estimated of 10% of worldwide population is affected by CKD. According to the Centers for Disease Control and Prevention (CDC), more than 26 million Americans are affected by CKD. CKD leads to end stage renal disease (ESRD) if untreated. It was estimated by the National Kidney Foundation in 2015 that about 468,000 ESRD patients are on dialysis in the U.S. alone.
The lead analyst of the report commented “The chronic kidney disease drugs market is set to experience considerable growth over the next decade. The main growth drivers of this market are increasing prevalence of chronic kidney disease (CKD) worldwide, promising pipeline, approval of novel molecules, and increasing incidence of cardiovascular disorders and diabetes. One of the major restraints of the chronic kidney disease drugs market is patent expirations of some of the major brands which are likely to result in introduction of substitutes and cheaper biosimilars.”
Leading companies featured in the report include Pfizer, Amgen, Roche, Abbott, GlaxoSmithKline (GSK), Sanofi, Morepen Laboratories, Baxter, Allergan, Japan Chemical Research Pharmaceuticals Co., Ltd.)
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.
04 June 2019
here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.